Eculizumab resistance management

Eculizumab (Eculizumab) is a monoclonal antibody targeting the C5 complement molecule and is mainly used to treat complement-mediated diseases. For the treatment of resistance to eculizumab, evaluation and treatment need to be based on the patient's specific situation, such as medical history, symptoms and laboratory test results. First, resistance usually means that the patient's condition is not controlled as expected, the treatment plan may need to be re-evaluated, and there may be other underlying causes or diagnoses that lead to resistance to eculizumab.

If a patient develops resistance while receiving eculizumab, increasing the dose of eculizumab may improve the patient's response in some cases. However, this requires a physician to evaluate the patient on a case-by-case basis and ensure that the patient can tolerate higher doses. In addition to eculizumab, other treatments may help a patient's condition. For example, the combination of other immunosuppressants or biologics may help improve a patient's response. If other treatments don't work or the patient develops resistance to other treatment options, doctors may consider switching to other drugs or treatment options.

The generic drug Eculizumab has been launched in China and is covered by medical insurance. It is only available for reimbursement to eligible patients. The specification is 300mg (30ml) and the price per box may be more than 3,000 yuan. It is understood that the price of each box of the original Eculizumab drug sold overseas is more than 6,000 US dollars (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold at home and abroad are basically the same, and the price of the original drug is still relatively expensive. There are currently no generic versions of eculizumab available on the market.